STRATEC SE

Earnings Release • Nov 8, 2018

STRATEC9M 2018 Financial Results

Conference Call – November 8, 2018

Forward-looking statements involve risks.

This company presentation contains various statements concerning the future performance of STRATEC. These statements are based on both assumptions and estimates. Although we are convinced that these forward-looking statements are realistic, we can provide no guarantee of this. This is because our assumptions involve risks and uncertainties which could result in a substantial divergence between actual results and those expected.

It is not planned to update these forward-looking statements.

• 1. FINANCIAL REVIEW
• 1. EARNINGS IMPROVEMENT INITIATIVE
• 1. OUTLOOK
• 1. FOCUS IN 2018 AND BEYOND
• 1. Q&A

• • Organic sales decline of 4.8% to € 134.6 million; nominal: -9.9% (9M 2017: € 149.4 million):

• -Negative effects from first time adoption of IFRS 15 and foreign exchange rates
• Reduced systems sales, weaker Diatron business and temporary slowdown in the demand for service parts & consumables
• • Assumption of significant upturn in growth momentum in Q4 2018 and 2019 as a whole confirmed by latest developments
• • Adjusted EBIT margin down by 370 bps yoy to 12.7% due to missing economies of scale and increased expenses related to strong project pipeline
• •Further contract wins and several promising negotiations in advanced stage
• • Identified annual pre-tax cost savings potential of € 2.0 million to € 3.0 million from 2021 onwards
• •Number of employees up by 12.4% to 1,208 in the light of full project pipeline

2. FINANCIAL REVIEW

• 1. EARNINGS IMPROVEMENT INITIATIVE
• 1. OUTLOOK
• 1. FOCUS IN 2018 AND BEYOND
• 1. Q&A

FINANCIALS AT A GLANCE1

$\epsilon$ 000s	$9M$ 2018 2	$9M$ 2017 3	Change yoy	9M 2018 before adoption of IFRS 9 and IFRS 15	Change yoy
Sales	134,627	149,418	$-9.9%$	138,914	$-7.0%$
Adjusted EBITDA	21.960	29,586	$-25.8%$	23,456	$-20.7%$
Adjusted EBITDA margin (%)	16.3	19.8	$-350$ bp	16.9	$-290$ bp
Adjusted EBIT	17.044	24.513	$-30.5\%$	17.941	$-26.8%$
Adjusted EBIT margin (%)		16.4	$-370$ bp	12.9	$-350$ bp
Adjusted consolidated net income 4	13.598	19.167	$-29.1%$	14.264	$-25.6%$
Adjusted earnings per share $(\epsilon)^4$		1.61	$-29.2%$	.20	$-25.5%$
Earnings per share $(\epsilon)^4$	0.51	1.37	$-62.8%$	0.57	$-58.4%$

bps = basis points

1 For comparison purposes, adjusted figures exclude amortization resulting from purchase price allocations in the context of acquisitions and the associated reorganization expenses, as well as other non-recurring effects.

2 In accordance with IFRS 9 and IFRS 15.

3 Not retrospectively restated to reflect IFRS 9 and IFRS 15 (modified retrospective approach). Retrospectively restated to reflect the classification of the nucleic acid preparation business as a discontinued operation in accordance with IFRS 5 and correction in accordance with IAS 8.41.

4 Results from continuing operations.

FINANCIAL REVIEW

ADJUSTMENTS

EBIT

$\epsilon$ 000s	$01.01 - 09.30.2018$
Adjusted EBIT	17,044
Adjustments • Expenses in connection with transactions and related restructuring expenses • PPA amortization • Impairments	$-1,571$ $-7,015$ $-642$
EBIT	7,816

Consolidated net income

€ 000s	$01.01 - 09.30.2018$
Adjusted consolidated net income from continuing operations	13,598
Adjusted earnings per share from continuing operations in $\epsilon$ (basic)	1.14
Adjustments • Expenses in connection with transactions and related restructuring expenses • PPA amortization • Impairments • Current tax expenses • Deferred tax income	$-1,571$ $-7,015$ $-642$ 619 1,140
Consolidated net income from continuing operations	6, 129
Earnings per share from continuing operations in $\epsilon$ (basic)	0.51

FINANCIAL REVIEW

SALES

9M 2018 sales decline:

• • Negative effects from foreign exchange rates (-2.2 ppts) and first-time adoption of IFRS 15 (-2.9 ppts)
• organic sales decline of 4.8%
• • Lower systems and service parts & consumables sales as well as weaker Diatron business
• • Current customer forecasts imply significant recovery for Q4 2018 and beyond

ppts = Percentage points

As of September 30

FINANCIAL REVIEW

ADJUSTED EBIT AND EBIT MARGIN

9M 2018 adjusted EBIT margin at 12.7%

• • Adjusted EBIT down 30.5% yoy to € 17.0 million
• Negative effect of € 0.9 million due to first-time adoption of IFRS 15
• • Margin decline of 370 bps yoy
• Negative scale effects
• Increased expenses related to strong project pipeline

As of September 30

CASH FLOW AND NET DEBT

I F R S ( € i l l i ) m o n	9 M 2 0 1 8	9 M 2 0 1 7	y o y
C h f lo in t a s w op e ra g – iv i ie t t a c s	1 5. 4	2 5. 8	4 0. 3 % -
C f h lo inv t t a s w e s m e n – iv i ie t t a c s	3. 9 -	9. 7 -	5 9. 8 % -
C f f h lo in in a s w a nc g – iv i ie t t a c s	9. 9 -	1 6. 1 -	3 8. 5 % -
Fr h f lo e e c a s w	1 1. 5	1 6. 1	2 8. 6 % -

I F R S ( € i l l i ) m o n	9 M 2 0 8 1	F Y 2 0 1 7	C h a n e g
C h d h le iv t a s a n c a s eq u a n s d f p d io t a e n o e r	2 5. 1	2 4. 1	4. 1 %
N de b t t e	4 4. 2	4 8. 8	9. 4 % -

• • 9M 2018 operating cash flow down by 40.3% yoy due to lower earnings levels and higher inventories

• • Higher capex spending due to significant capacity expansion in Birkenfeld partly offset by disposal of financial assets

• 1. FINANCIAL REVIEW
• 1. EARNINGS IMPROVEMENT INITIATIVE
• 1. OUTLOOK
• 1. FOCUS IN 2018 AND BEYOND
• 1. Q&A

EARNINGS IMPROVEMENT INITIATIVE

Operational Efficiency

• •Increase volume of insourced subassemblies
• •Streamlining geographical R&D and production footprint
• •Implementation of group wide ERP-system

Portfolio Optimizations

• • Disposal of nucleic acid sample preparation business (sales of € 2.5 million and EBIT-loss of € 0.9 million in 2017)
• •Selective discontinuation of some smaller/end-of-life cycle and less profitable product lines

Focused Allocation of Development Resources

• •Optimizing R&D opportunity costs
• •Optimizing risk reward profile of development pipeline

Expected annual pre-tax cost savings of € 2.0 million to € 3.0 million from 20211) onwards

12

• 1. FINANCIAL REVIEW
• 1. EARNINGS IMPROVEMENT INITIATIVE

4. OUTLOOK

• 1. FOCUS IN 2018 AND BEYOND
• 1. Q&A

OUTLOOK

FINANCIAL GUIDANCE

Outlook for 2018

• •Sales expected to decline organically in the low- to mid-single digit percentage range
• •Adjusted EBIT margin of around 11% to 13%

First indication for 2019

• • Significantly positive organic sales growth expected in 2019
• -Numerous upcoming product launches and ongoing ramp-up phases
• -Partial postponement of sales originally expected for 2018
• • Adjusted EBIT margin to be significantly higher than the level of 2018
• -Positive scale effects

• -First positive impact from already defined earnings improvement measures

• 1. FINANCIAL REVIEW
• 1. EARNINGS IMPROVEMENT INITIATIVE
• 1. OUTLOOK
• 1. FOCUS IN 2018 AND BEYOND
• 1. Q&A

FOCUS IN 2018 AND BEYOND

• • Reaccelerate top-line growth from Q4 2018 onwards and reduce earnings volatility across business units
• •Further realize synergies through development activities across STRATEC businesses
• •Leverage expanded platform offering
• • Achieve milestones and market launches within foreseen timeframe
• • Expected launches within the next couple of months among others include instruments for DiaSorin, Becton Dickinson, Quotient and the KleeYa Analyzer platform
• •Drive results from defined earnings improvement initiative
• •Implementation of a group-wide ERP system to further drive process efficiency
• •Expand development capacities including significant extension of buildings in Birkenfeld

QUESTIONS & ANSWERS

9M 2018 FINANCIAL RESULTS – NOVEMBER 8, 2018 17

CONTACT

STRATEC Biomedical AGGewerbestr. 3775217 BirkenfeldGermany

www.stratec.com

CONTACT

Marcus Wolfinger CEO

Jan Keppeler, CFA Head of Investor Relations & Corporate Communications Phone +49 7082 7916-6515Fax +49 7082 7916-9190j.keppeler@stratec.com

THANK YOU FOR YOUR ATTENTION